Advances in the diagnosis and treatment of cystic fibrosis. (Q38231006)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Advances in the diagnosis and treatment of cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Stacey L Martiniano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jordana E Hoppe

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Scott D Sagel

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

1 reference

3 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Advances in pediatrics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

225-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Personalized medicine in cystic fibrosis: dawning of a new era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

A Novel Mutation in the Cystic Fibrosis Gene in Patients with Pulmonary Disease but Normal Sweat Chloride Concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Atypical cystic fibrosis and CFTR-related diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Modifier genes in Mendelian disorders: the example of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Gastrointestinal outcomes and confounders in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Genotype and phenotype in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

CFTR2: How will it help care?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

CFTR biomarkers: time for promotion to surrogate end-point.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Benchmarking to improve the quality of cystic fibrosis care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of high-dose ibuprofen in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2013; focus theme: age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

Anxiety, depression, and life satisfaction in parents caring for children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2014.03.002

10.1016/J.YAPD.2014.03.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037130%20AND%20SRC:MED&resulttype=core&format=json